Navigation Links
iZumi Bio and Pierian Merge to Form iPierian to Advance Cellular Reprogramming
Date:7/7/2009

SOUTH SAN FRANCISCO, Calif. and BOSTON, July 8 /PRNewswire/ -- iZumi Bio, Inc. and Pierian, Inc. today announced they have merged to form a new company, iPierian, Inc. Building on the iZumi infrastructure and vision, the company is focused on the application of cellular reprogramming to change the paradigm of drug discovery. The scientific leadership of the company will accelerate the development of new therapeutics using induced pluripotent stem (iPS) cells for patients with difficult-to-treat diseases.

iPierian is rapidly building upon the experienced management and scientific team of iZumi, who have deep knowledge and experience in both stem cell technology and drug discovery. The company will be led by John P. Walker, currently the chief executive officer of iZumi. Dr. Berta Strulovici will head up research efforts as the chief technical officer of iPierian and Dr. Dushyant Pathak will lead the company's business development activities. Dr. Corey Goodman, recently the president of Pfizer's Biotherapeutics and Bioinnovation, an elected member of the U.S. National Academy of Sciences, and a board member of iZumi, will become chairman of the Board of Directors of iPierian.

The scientific founders of Pierian, Drs. George Daley, Douglas Melton and Lee Rubin, faculty members at Harvard University, will become actively involved in decisions regarding the scientific direction and research priorities for iPierian. Dr. Daley will co-chair the new Scientific Advisory Board (SAB) of iPierian together with Dr. Deepak Srivastava, director of the Gladstone Institute of Cardiovascular Disease and professor at the University of California San Francisco (UCSF). Dr. Corey Goodman will also sit on the company's SAB, and will be joined by a cadre of leading stem cell scientists.

"Since the inception of iZumi, we have built an organization and a platform of cellular programming as it applies to drug d
'/>"/>

SOURCE iZumi Bio, Inc.; Pierian, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. The Gladstone Institutes and iZumi Bio Announce Broad Partnership in Regenerative Medicine and Cardiovascular Disease
2. iZumi Bio, Inc. Recruits Leading iPS Scientist, John Dimos, to Translate Stem Cell Breakthrough Into Patient Benefits
3. iZumi Bio, Inc., Appoints John Walker as Chief Executive Officer
4. iZumi Bio Appoints Dr. Berta Strulovici as Chief Technology Officer and Dr. Dushyant Pathak as Vice President of Business Development
5. iZumi Bio Appoints Dr. Corey Goodman to Board of Directors and Scientific Advisory Board
6. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
7. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
8. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
9. ev3 and FoxHollow Announce Date for Special Meeting of FoxHollow Stockholders to Vote on Proposed Merger
10. IsoTis - Integra Merger
11. New Brunswick Scientific Completes Merger Transaction with Eppendorf
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... analysis of patented university inventions licensed to biotechnology ... to commercialization. To open these roadblocks, the researchers ... during the discovery stage could lead to faster ... frequently derived from discoveries made in university laboratories ... known during clinical trials, which have a high ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 High ... and apply the most complete climate and Earth ... demanding climate change issues. , Eight national laboratories, ... with the National Center for Atmospheric Research, four ... new effort. Other participating national laboratories include Argonne, ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 Not long ... E&L studies should be performed late in the development ... known. But current regulatory trends suggest that, like many ... the rise. In recent years, multiple drug sponsors have ... or address specific questions during phase I/II. It’s not ...
(Date:8/20/2014)... Sofia, Bulgaria (PRWEB) August 20, 2014 ... was released today including improvements to the ... rates and connectors for Lucene, SOLR and Elasticsearch. ... change for this high performance triplestore – GraphDB™ ... organizations interested in deploying the only mature enterprise ...
Breaking Biology Technology:Early bottlenecks in developing biopharmaceutical products delay commercialization 2Early bottlenecks in developing biopharmaceutical products delay commercialization 3New Project Is the ACME of Addressing Climate Change 2New Project Is the ACME of Addressing Climate Change 3Are Extractable and Leachables going Phase-Appropriate? New Webinar Hosted by Xtalks 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 3Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 4
... - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI , ... second quarter ended June 30, 2009. , "We were ... Medical Products business during the quarter, including continued acceleration ... said Dr. William Hunter, President and CEO of Angiotech. ...
... , , SEATTLE, Aug. ... reported recent achievements and financial results for the second quarter and ... "The second quarter of 2009 was a transforming quarter for the ... III data at the American Society of Clinical Oncology Annual Meeting ...
... , NEW YORK, Aug. 5 ... biopharmaceutical company focused on the acquisition, development and commercialization ... of life-threatening diseases, including renal disease and cancer (the ... ended June 30, 2009. , , ...
Cached Biology Technology:Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009 2Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009 3Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009 4Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009 5Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009 6Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009 7Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009 8Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009 9Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009 10Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009 11Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009 12Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009 13Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009 14Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009 15Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009 16Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009 17Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009 18Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009 19Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009 20Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009 21Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009 22Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009 23Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009 24Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009 25Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009 26Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009 27Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009 28Cell Therapeutics Second Quarter Net Loss Decreases 54%; Pixantrone NDA Submitted to the FDA for Approval 2Cell Therapeutics Second Quarter Net Loss Decreases 54%; Pixantrone NDA Submitted to the FDA for Approval 3Cell Therapeutics Second Quarter Net Loss Decreases 54%; Pixantrone NDA Submitted to the FDA for Approval 4Cell Therapeutics Second Quarter Net Loss Decreases 54%; Pixantrone NDA Submitted to the FDA for Approval 5Cell Therapeutics Second Quarter Net Loss Decreases 54%; Pixantrone NDA Submitted to the FDA for Approval 6Cell Therapeutics Second Quarter Net Loss Decreases 54%; Pixantrone NDA Submitted to the FDA for Approval 7Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results 2Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results 3
(Date:8/20/2014)... approximately 3 million infants, a team of scientists across ... Massachusetts Medical School, have shown that newborn screening for ... public health newborn screening programs. Data from 11 newborn ... the Journal of the American Medical Association ... newborns is higher than previously thought and believed to ...
(Date:8/20/2014)... have suffered concussions ready to return to action? A ... school athletes who head back on the field with ... in their abilities to simultaneously walk and do simple ... in their balance and/or altered walking speed, was found ... had returned to activity in less than a month. ...
(Date:8/20/2014)... could one day be made out of cocoa, rice ... reporting. The novel process they developed and their results, ... and plastic waste problems, appear in the ACS journal ... and colleagues at the Italian Institute of Technology point ... its production reached 288 million tons worldwide, but its ...
Breaking Biology News(10 mins):Newborn screening expansion offers early diagnosis and treatment to infants with SCID 2Newborn screening expansion offers early diagnosis and treatment to infants with SCID 3Recovery reversal seen in Oregon study of returning concussed athletes 2Recovery reversal seen in Oregon study of returning concussed athletes 3
... the health of the world,s oceans down a rapid ... or perhaps ultimately reverse the catastrophic problems they are ... a professor of oceanography at Scripps Institution of Oceanography ... of the oceans and their ecological health. Publishing his ...
... A critical component of NASA,s Mars exploration program ... in-depth analysis, plans for which are detailed in ... peer-reviewed journal published by Mary Ann Liebert, Inc. ... www.liebertpub.com/ast In the published report entitled, ...
... newly developed robot capable of diving as deep ... has been successfully completed by scientists and engineers ... the University of Washington (UW). The vehicle ... for seafloor instruments that will be deployed in ...
Cached Biology News:Oceans on the precipice: Scripps scientist warns of mass extinctions and 'rise of slime' 2Oceans on the precipice: Scripps scientist warns of mass extinctions and 'rise of slime' 3Bringing Martian samples to Earth -- preparations outlined in journal Astrobiology 2Robot vehicle surveys deep sea off Pacific Northwest 2Robot vehicle surveys deep sea off Pacific Northwest 3
... The "egg crate" style strip holder is ... bottom strips. Linkage: This CLS number is ... match Cornings product number. If showing no ... Sigma-Aldrich number (Z71,456-9) or contact customer service ...
... Streptavidin-AP Systems provide rapid, precise localization ... in frozen or paraffin-embedded tissue, cytospins ... also facilitate double or triple labeleing ... simultaneously with primary antibodies of different ...
Designed for use with all 96-well SPRI reagent kits. Used with round bottom 96-well microplates, and 96-well thermal cycling plates....
... pre-amplifier suitable for a broad range of ... recording physiological signal such as ECG, EMG, ... for use with a wide range of ... a stimulus artefact clamp to avoid saturation ...
Biology Products: